Higher BMI, Bigger Gains: Tirzepatide's Effects on HFpEF
In patients with obesity-related heart failure with preserved ejection fraction (HFpEF), tirzepatide reduced the risk for worsening heart failure or cardiovascular death regardless of their baseline BMI or fat distribution, with larger gains observed among those with higher BMI. Those who lost more weight with tirzepatide showed greater improvements in exercise capacity and symptom severity.
METHODOLOGY:
The SUMMIT trial previously showed significant benefits of tirzepatide, a long-acting glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, in patients with obesity-related HFpEF.
In this secondary analysis, researchers looked at whether the effects of tirzepatide varied with the severity and distribution of a patient's obesity or by the extent of weight loss achieved after treatment.
The trial included 731 patients aged 40 years or older (mean age, 65.2 years; 53.8% women) with obesity-related HFpEF (defined by the New York Heart Association's functional classes II-IV) and a BMI of 30 or higher.
Participants were randomly assigned to subcutaneously receive either 2.5 mg/wk of tirzepatide (n = 364) or a placebo (n = 367).
Patients were categorized into tertiles of their baseline BMI and waist to height ratio.
Primary endpoints were the time to first adjudicated cardiovascular death or an event of worsening HF and a change in the symptom status measured using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) at 52 weeks. Secondary endpoints included changes in exercise capacity (measured using the 6-minute walk distance), body weight, and blood pressure.
TAKEAWAY:
Patients in the highest tertile of BMI were younger and most likely to be women and had more severe HF, a greater volume overload, and more severe inflammation. Those with a higher waist to height ratio showed similar patterns, as well as shorter 6-minute walk distances and more severe kidney disease.
Use of tirzepatide vs placebo reduced the risk for cardiovascular death or worsening HF across all BMI ranges and waist to height ratios.
Tirzepatide was associated with greater improvement in the 6-minute walk distance in patients in the highest range for BMI (37.5 m) than in those in the middle (26.3 m) and lower (9.9 m) ranges (P for trend = .025); improvements in weight loss and systolic blood pressure followed similar patterns.
After 52 weeks on tirzepatide, those who lost more weight had bigger gains in their 6-minute walk distance and changes in the KCCQ-CSS (P < .0001 for both). The same benefits were seen in those with larger drops in waist circumference.
IN PRACTICE:
'These data provide further evidence supporting the importance of excess body fat, particularly visceral fat, as driving HF severity in patients with the obesity phenotype of HFpEF,' the researchers reported.
'While these findings reinforce the role of incretin therapies in HFpEF management, these data, perhaps more importantly, highlight the urgent need for precision strategies to define obesity and direct therapy to those who will benefit most,' experts wrote in an editorial accompanying the journal article.
SOURCE:
This study was led by Barry A. Borlaug, MD, of Mayo Clinic in Rochester, Minnesota. It was published online on July 21, 2025, in the Journal of the American College of Cardiology. The researchers presented the findings at the American College of Cardiology (ACC) Scientific Session 2025.
LIMITATIONS:
Categorizing patients into tertiles of their BMI or waist to height ratio may have masked some trends. The trial included a higher proportion of women and participants from Latin America, limiting generalizability. Imaging-based methods could possibly offer more precise measurements of obesity.
DISCLOSURES:
The original trial was funded by Eli Lilly and Company. The lead author reported receiving grants from the National Heart, Lung, and Blood Institute and US Department of Defense, receiving research grants from and consulting for several pharmaceutical companies, and being a named inventor for tools and approach for procedure to treat HF. Several other authors reported being employees of or consultants for Eli Lilly and Company and several other companies.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
UPDATE -- HT Vet Survey Reveals HT Vista's Ability to Increase Revenue for Veterinary Clinics
Clinics using the device empower their clinicians with precise cancer risk scoring, driving better outcomes and clinic efficiency HILLSIDE, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- HT Vet, the veterinary health technology company behind HT Vista, the only non-invasive, first-line cancer detection tool for dogs, today announced survey results showing that veterinary practices using the device experienced a 40% increase in mass removal surgeries. The data, collected from ten veterinary practices across the US, UK, and Israel, tracked the number of lumpectomies performed three to six months before and after the introduction of HT Vista. Despite consistent caseloads, all clinics reported an increase in mass removals and biopsies following the device's adoption. Some clinics reported increases as high as 200%, without any corresponding rise in the number of dogs needing lump investigations. This increase in lumpectomies is directly correlated with increased revenue for these clinics. 'I use HT Vista to tell me what to do next,' said Dr. Ohad Barnea, Clinical Director and Co-owner, Tenafly Veterinary Center. 'If I get a high cancer risk result, I recommend diagnostics or removal more urgently, and I will aspirate to check what it is. This helps determine the [surgical] margins I'll need. If it's a low cancer risk result, we might do a minor surgical removal with local anesthesia, preventing benign tumors from becoming problematic. HT Vista provides critical guidance for the next steps, and the clients love the clarity and assurance it gives them.' Outside of the group studied, most clinics reported achieving a positive ROI within four to six months after adopting HT Vista. This is largely due to HT Vista's ability to provide clinicians with a Cancer Risk Score featuring 90% sensitivity and 98% negative predictive value, along with a diagnostic alert when cancer detection specificity exceeds 90%. A 40-second scan with HT Vista's heat diffusion imaging flags masses that require further investigation, eliminating the uncertainty of the 'wait and see' approach. As a result, more dogs receive the diagnostic and surgical care they need. Veterinarians can discuss treatment options with greater confidence, making faster and more informed decisions. 'These results confirm what we've long believed, that giving veterinary teams access to fast, non-invasive cancer screening leads to more confident decision-making and better use of clinic resources,' said Shani Toledano, CEO of HT Vet. 'HT Vista isn't just helping detect potential cancers earlier, it shortens the time between detection and treatment, improving outcomes for dogs, providing peace of mind for their owners, and empowering clinicians to deliver greater value to both patients and the clinic's bottom line.' HT Vet aims to bring HT Vista into every veterinary clinic worldwide. Earlier this year, the company partnered with Patterson Veterinary, one of North America's largest veterinary product distributors, to increase accessibility of HT Vista across the U.S. This partnership, combined with ongoing strategic initiatives, expands access so more veterinary practices worldwide can benefit from HT Vista's proven ability to improve patient outcomes and increase returns. To see detailed survey results, click here. About HT Vet HT Vet is an Israeli-based company aiming to increase early detection of dermal and subcutaneous cancer in dogs. Its revolutionary, patented medical imaging technology, Heat Diffusion Imaging, was developed by a team of experts in the fields of AI, signal analysis, and computer vision, together with top researchers in heat transfer and thermodynamics, oncologists, and radiologists. For more information about the HT Vista device or to schedule a demonstration, please visit HT Vet's website. Media Contact Shahni Ben-HaimSBH Media Relationsshahni@ A photo accompanying this announcement is available at
Yahoo
an hour ago
- Yahoo
A judge blocked a rule to drop medical debt from credit reports. What now?
A recent federal court ruling overturned a Biden-era ban on medical debt in credit reports just as access to healthcare and health insurance is becoming more fragile. The decision could thwart the hopes of an estimated 15 million Americans who might have seen some relief ahead of expected hikes to healthcare premiums, the end of enhanced marketplace subsidies, and an anticipated increase in the number of Americans without insurance. 'We're really concerned that with the loss of insurance altogether, or healthcare becoming more expensive, we're just going to see more medical debt,' said Mona Shah, the senior director of policy and strategy at Community Catalyst, a national nonprofit healthcare advocacy organization. 'With this protection removed around credit reporting, it's going to impact people's overall economic well-being and ability to thrive.' A $49 billion reversal Earlier this month, a federal judge blocked a rule from the Consumer Financial Protection Bureau (CFPB), which had never taken effect, that would have stopped medical bills from appearing on credit reports and barred lenders from using such data to make lending decisions. The CFPB estimated the change could raise impacted consumers' credit scores by an average of 20 points. Healthcare providers typically don't report missed medical bills directly to credit bureaus, according to Equifax, so medical debt often doesn't wind up on a credit report until it's been reported to a collections agency. However, two trade associations successfully argued that the CFPB had overstepped its authority. Under the Trump administration, the CFPB also asked for the rule to be thrown out. In a July 11 ruling, Judge Sean Jordan of the US District Court for the Eastern District of Texas agreed with the trade groups. The ruling comes at an especially precarious time in healthcare. The tax bill signed into law by President Trump this month is expected to leave 10 million Americans without health insurance by 2034, largely due to changes in Medicaid. Meanwhile, enhanced premium tax credits that helped make Affordable Care Act marketplace coverage more affordable will expire at the end of this year after they were not extended in the tax bill, a change that will help contribute to the largest premium increases seen in years in 2026. The end of the subsidies is expected to leave an estimated 4.2 million people uninsured. 'Having more people lose Medicaid and become uninsured, and also lower-income adults losing subsidized marketplace coverage and becoming uninsured, is going to significantly increase medical debt,' said Fredric Blavin, a senior fellow and researcher at the Urban Institute, a Washington-based think tank. Under the Biden administration, the CFPB estimated that removing medical bill information could have wiped $49 billion off the credit reports of about 15 million Americans, noting that medical billing information often contained errors and was a poor predictor of a consumer's creditworthiness. Lower credit scores can damage a person's ability to rent a home, obtain a credit card with a favorable rate, and even impact their job search. In public comments supporting the rule, many Americans shared stories of how medical bills had weighed on their credit, including cancer patients, people who had been in car wrecks, and more. Read more: How are credit scores calculated? Sign up for the Mind Your Money weekly newsletter By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy What should consumers do now? Credit reporting agencies had already voluntarily decided in April 2023 to wipe medical collection debt from consumer credit reports if the balance was below $500. A year earlier, paid medical collection debt was also dropped from credit reports, and consumers were given one year to pay down medical collection debt before it started appearing on their credit reports, rather than six months. Additionally, the CFPB noted that FICO and VantageScore had previously both 'decreased the degree to which medical bills impact a consumer's score.' These combined changes dropped medical debt in collections from most consumers' credit reports, the Urban Institute found, leaving about 4.1% of adults with such data on their records in August 2024, down from 12.6% in February 2022. Additionally, 14 states have provisions in place to remove medical collection debt from credit reports. 'We expect more states to take the same initiative moving forward,' said Breno Braga, a senior fellow and researcher at the Urban Institute. Still, consumers are left with the onerous job of keeping up with these changes and staying on top of their credit as they face mounting bills — along with the resumption of delinquent student loans hitting credit scores. Consumers should regularly check their mail and email for information concerning their credit, while also carefully examining the bills to determine what they owe and what they might be able to contest. When it comes to unaffordable medical care, consumers can ask healthcare providers about financial assistance options. Read more: How to check your credit score for free 'It's really just vigilance and trying to understand what's available in terms of assistance,' said Sarah Chenven, the CEO of Working Credit, a nonprofit organization that helps people build good credit. Consumers should also be cautious about signing up for medical credit cards with a 'deferred interest', said Shah with Community Catalyst, which may subject them to high, retroactive interest charges if they don't pay their bill in a certain promotional period. 'When patients are now faced with these difficult decisions of not being able to pay off these bills right away — worried about how it's going to impact their credit scores, losing their insurance, still needing healthcare — they may be lured into signing up for one of these payment products,' said Shah. Emma Ockerman is a reporter covering the economy and labor for Yahoo Finance. You can reach her at Sign up for the Mind Your Money newsletter Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
BEACHWOOD, Ohio, July 23, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells at scale for drug discovery and cell therapy, introduces TrailBio® A9 Dopaminergic Neurons, a powerful new tool available off-the-shelf for studying Parkinson's disease and other neurodegenerative conditions. A9 dopaminergic neurons play a critical role in movement regulation and are disproportionately affected in Parkinson's disease. Historically, researchers have lacked access to viable human models, relying instead on animal studies with limited relevance. With TrailBio® A9 Dopaminergic Neurons, scientists now have a human-specific platform to investigate disease mechanisms, develop therapies and accelerate drug discovery. "TrailBio® A9 Dopaminergic Neurons open new possibilities for Parkinson's research," said Dr. Jan Jensen, Chief Scientific Officer, Chief Technology Officer and founder of Trailhead Biosystems. "These cells enable researchers to study the vulnerabilities of A9 neurons, helping drive progress toward more effective treatments." "For decades, the lack of human A9 neurons has limited our ability to truly understand Parkinson's disease," added Dr. Nooshin Amini, Scientific Director at Trailhead Biosystems. "Now, with TrailBio® A9 Dopaminergic Neurons, researchers can directly study the exact cells that are most affected, offering hope for groundbreaking insights and future therapies." About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® A9 Dopaminergic Neurons represent one of many specialized human cell types emerging from this platform, with additional cell models expected in the near future. Learn more about Trailhead Biosystems, TrailBio® A9 Dopaminergic Neurons and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia:
